Stocks and Investing Stocks and Investing
Tue, January 31, 2023
Mon, January 30, 2023

Etzer Darout Maintained (YMAB) at Buy with Increased Target to $13 on, Jan 30th, 2023


Published on 2024-10-28 01:12:52 - WOPRAI, Etzer Darout
  Print publication without navigation


Etzer Darout of BMO Capital, Maintained "Y-mAbs Therapeutics, Inc." (YMAB) at Buy with Increased Target from $12 to $13 on, Jan 30th, 2023.

Etzer has made no other calls on YMAB in the last 4 months.



There are 7 other peers that have a rating on YMAB. Out of the 7 peers that are also analyzing YMAB, 3 agree with Etzer's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Joseph Thome of "Cowen & Co." Downgraded from Buy to Hold on, Thursday, January 5th, 2023
  • Alec Stranahan of "B of A Securities" Maintained at Hold with Increased Target to $6 on, Thursday, December 15th, 2022
  • David Nierengarten of "Wedbush" Downgraded from Buy to Hold and Held Target at $6 on, Monday, October 31st, 2022


These are the ratings of the 4 analyists that currently disagree with Etzer


  • Michael Ulz of "Morgan Stanley" Downgraded from Hold to Sell on, Friday, January 27th, 2023
  • Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $19 on, Monday, October 31st, 2022
  • Tessa Romero of "JP Morgan" Downgraded from Hold to Sell and Decreased Target to $7 on, Monday, October 31st, 2022
  • William Maughan of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $27 on, Monday, October 31st, 2022
Contributing Sources